Sabirnetug
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Sabirnetug
- acu 193
- ACU-193
- acu193
- Acu193
- ACU193
- Immunoglobulin G2 [264-histidine,305-valine,326-alanine,327-proline], anti-(human Aβ oligomer) (human-Mus musculus monoclonal ACU193 g2-chain), disulfide with human-Mus musculus monoclonal ACU193 k-chain, dimer
- immunoglobulin g2 264 histidine 305 valine 326 alanine 327 proline anti human aβ oligomer human mus musculus monoclonal acu193 g2 chain disulfide with human mus musculus monoclonal acu193 k chain dimer
- immunoglobulin g2 kappa anti homo sapiens app amyloid beta a4 precursor protein abeta42 and abeta40 soluble non fibrillar oligomers humanized monoclonal antibody gamma2 heavy chain humanized 1 443 vh homo sapiens ighv3 48 01 92 9 ighd ighj4 01 92 9 cdr imgt 8 8 10 26 33 51 58 97 106 1 117 homo sapiens ighg2 01 g2m ch2 v45 1 ch1 118 215 hinge 1 12 216 227 ch2 v45 1 278 228 336 ch3 337 441 chs 442 443 118 443 131 219 disulfide with kappa light chain humanized 1 219 v kappa homo sapiens igkv2 28 01 89 5 igkj2 03 100 cdr imgt 11 3 9 27 37 55 57 94 102 1 112 homo sapiens igkc 01 km3 a45 1 158 v101 196 113 219 dimer 219 219 220 220 223 223 226 226 tetrakisdisulfide produced in chinese hamster ovary cho cells glycoform alfa
- immunoglobulin G2-kappa, anti-[Homo sapiens APP (amyloid beta A4 precursor protein) Abeta42 and Abeta40 soluble non-fibrillar oligomers], humanized monoclonal antibody; gamma2 heavy chain humanized (1-443) [VH (Homo sapiens IGHV3-48*01 (92.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.10] (26-33.51-58.97-106)) (1-117) -Homo sapiens IGHG2*01, G2m.. CH2 V45.1 (CH1 (118-215), hinge 1-12 (216-227), CH2 V45.1 (278) (228-336), CH3 (337-441), CHS (442-443)) (118-443)], (131-219')-disulfide with kappa light chain humanized (1'-219') [V-KAPPA (Homo sapiens IGKV2-28*01 (89.5%) -IGKJ2*03 (100%), CDR-IMGT [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo sapiens IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (219-219'':220-220'':223-223'':226-226'')-tetrakisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
- sabirnetug
- Sabirnetug
- sabirnetug (ACU193)
- sabirnetug [INN]
- SABIRNETUG [USAN]
- sabirnetug inn
- sabirnetug usan
- CAS registry numbers
- 2747959-38-0
- ChEMBL ID
- CHEMBL5314772
- FDA ingredient codes (UNII)
- 2U1A25MKP9
- First in class
- No
- Orphan designation
- No
Investigated indications
- Condition
- Alzheimer Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
Open Targets indications
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 2
- NCT04931459
- NCT06335173
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- 293 $ 293''
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISRGSSTIYYADTVKGRETISRDNAKNSLYLQMNSLRAEDTAVYYCARGITTALDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTEPAVLQSSGLYSLSSVVTVESSNEGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVELFPPKPKDTLMISRIPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREBQVYTLEPSREEMTENQVSLICLVKGFYPSDIAVEWESNGQPENNYRTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVESCSVMHEALHNHYTQKSLSLSPGK
- Component
- Light chain
- Type
- Protein
- Sequence
- DVVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKASNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSRLGPSFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSENRGEC
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-93 $ 23'''-93''' $ 131-219' $ 131''-219''' $ 139'-199' $ 139'''-199''' $ 144-200 $ 144''-200'' $ 219-219'' $ 220-220'' $ 223-223'' $ 226-226'' $ 257-317 $ 257''-317'' $ 363-421 $ 363''-421''
Related records
Trials (3)
- A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
- A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
- A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
In development for (1)
- Alzheimer disease Phase 2